Genetics company 23andMe is rolling out a huge initiative for people with ADHD and depression - but psychologists are worried
- Genetics testing company 23andMe recently launched a feature that allows customers to share information about what treatments for 18 conditions - including depression and ADHD - do and don't work for them.
- Outside experts call the feature "concerning" and say it could mislead people or discourage them from getting the proper treatment.
- The feature currently has more than 5,000 users, 23andMe says.
In a move that psychologists and psychiatrists are calling "concerning," popular genetics company 23andMe launched an initiative earlier this month allowing customers to share tips about which treatments for conditions including ADHD and depression do or don't work for them.
View all Offers
OnePlus Nord 2 5G (Gray Sierra, 8GB RAM, 128GB Storage) I Extra upto Rs.1000 off on Exchange₹ 29999Buy On
- 19% OFF
Redmi Note 10 (Aqua Green, 4GB RAM, 64GB Storage) -Amoled Dot Display | 48MP Sony Sensor IMX582 | Snapdragon 678 Processor₹ 12999₹ 15999Buy On
OnePlus Nord 2 5G (Blue Haze, 8GB RAM, 128GB Storage) I Extra upto Rs.1000 off on Exchange₹ 29999Buy On
- 18% OFF
Redmi 9A (Nature Green, 2GB RAM, 32GB Storage) | 2GHz Octa-core Helio G25 Processor | 5000 mAh Battery₹ 6999₹ 8499Buy On
- 18% OFF
Redmi 9 (Carbon Black, 4GB RAM, 64GB Storage) | 2.3GHz Mediatek Helio G35 Octa core Processor₹ 8999₹ 10999Buy On
Although the pages are similar to what someone might find on Google or Reddit (in the sense that anyone can comment on them and share information), experts warn that they might carry a feeling of authority that could encourage some customers to believe that the content has been vetted by a scientist, physician, or researcher."There's a worry with having that authority label," Nancy Liu, an assistant clinical professor of clinical psychology at the University of California at Berkeley, told Business Insider.
Cristina Cusin, a psychiatrist at Massachusetts General Hospital and an assistant professor at Harvard University, agreed. She is worried that customers may treat the condition pages similar to the way they'd treat a medical consultation with a physician, despite a disclaimer at the bottom which reads, "Keep in mind that this content is preliminary and meant for informational purposes only."
There are other problems with the new feature as well, experts say.One of them is what Liu calls selection bias. Essentially, "you self-select individuals who are engaging in this dialogue, which skews the type of information you receive, but it's somehow viewed to represent all of individuals with a particular condition."
Customers might assume that 23andMe's pages provide provide a comprehensive look at everyone with depression or ADHD, when in reality, they only represent people with the condition who also had the time and interest to get online and discuss their condition with others.
Another issue is that the feature bundles all people with a condition like depression under the same label. The true nature of depression is much more complex than that, Liu said.That recognition is vital to ensuring that people with a wide range of iterations of the disorder get the individualized treatment that works for them - whether it's antidepressants, individual therapy, group therapy, or a combination of all three.
The "treatments" currently shown on the conditions pages are nowhere near exhaustive. Not all of them are necessarily considered treatments in and of themselves. While exercising and having a pet, for example, are near the top of 23andMe's list of beneficial treatments, a tool like cognitive behavioral therapy, one of the best studied and most helpful treatments for depression, is not on the list at all.Jesse Inchauspe, the product lead for 23andMe's condition pages, told Business Insider that the thinking behind the project was that the company had useful information besides just genetics information to share with customers.
She said the company chose the 18 conditions that are currently listed, which include depression, ADHD, asthma, and high blood pressure, based on their commonality among 23andMe customers. The company did not consult with medical experts prior to rolling out the platform, Inchauspe said.While the feature is currently only available to 50% of customers, the other half will have access to it this week, she said. Based on customer enthusiasm, she said that 23andMe plans to add more conditions in the near future."It's always been our mission to give people access to as much information as possible," Inchauspe said.
- Fino Payments Bank files papers for ₹1,300 crore IPO
- OfBusiness, a platform that helps SMEs get raw materials, becomes the newest unicorn from India
- Tokyo Olympics: India's P V Sindhu loses to world number one Tai Tzu Ying of Chinese Taipei in the semis
- Droom founder explains why he is considering a US IPO and where he intends to spend the money
- 21 new COVID-19 cases reported at Tokyo Olympics, no athletes among them